CompoundAtlas
Sign in

KPV

—
evidence score
peptide
Gray Market
Lysine-Proline-Valinealpha-MSH fragment

Tripeptide fragment of alpha-MSH that reduces inflammation by inhibiting NFkB activation, reducing TNF-alpha, IL-6, and IL-1beta. Works both systemically and locally in the GI tract.

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

Preclinical

Last Sync

Not synced yet

Last Reviewed

Not reviewed yet

Physician Notes

Part of the injury recovery stack. Oral form useful for GI inflammation. Injectable for systemic anti-inflammatory effect. Pending reclassification.

FDA Status:Category 2. Pending reclassification to Category 1.

Monitoring

  • Inflammatory markers (CRP, ESR) if indicated
  • Clinical assessment
Velix Health

Want this prescribed by a board-certified physician?

Velix Health physicians review your labs, build evidence-based protocols, and monitor your progress. Every prescription is referenced.

Apply for Membership

Dosing

Typical
1000 mcg
500 mcgRange1000 mcg
FrequencyDaily

Set height & weight in Settings to see your dose.

Pharmacology

Half-lifeMinutes
Routes
subcutaneous_injection
oral

Evidence Score

—
0 studies indexed
Scoring Factors
Volume(24%)—
Quality(24%)—
Sample Size(12%)—
Consistency(14%)—
Replication(8%)—
Recency(18%)—
Evidence Levels
AScore ≥75 with at least 1 meta-analysis and 3+ RCTs
BScore ≥50 with at least 1 RCT or meta-analysis
CScore ≥25 — observational or animal evidence only
DScore <25 — very limited or preclinical data

Plain-English Snapshot

KPV is currently categorized as a peptide compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Anti-inflammatory; reduces TNF-alpha and interleukins via NFkB inhibition

Practical Context

Strongest current signals

No indexed study summaries yet.

Compound Profile